The Federal Trade Commission and four states filed a lawsuit in federal court in Fort Worth, Texas, accusing the World Professional Association for Transgender Health of misleading doctors and families about the risks and benefits of gender-affirming care for minors.
The legal challenge targets the World Professional Association for Transgender Health, an organization that issues recommendations for the management of transgender patients. Filed Wednesday in the federal court in Fort Worth, the complaint brings together the federal trade agency and the states of Texas, Iowa, Nebraska, and Alaska in an effort to curb clinical practices for transgender youth.
Federal Allegations Over Suicide Claims and Financial Motives
According to the joint legal action, the organization misled medical professionals and parents by overstating the correlation between gender-affirming medical interventions and suicide prevention among children and adolescents experiencing gender dysphoria. The complaint characterizes gender dysphoria as a condition involving distress when a person’s gender identity does not match their assigned birth sex. Furthermore, the plaintiffs allege that the group sought to expand insurance coverage for these treatments to secure financial benefits for its members.
Broader Political Context and Regulatory Scrutiny
This lawsuit represents the latest initiative from the administration of President Donald Trump and Republican-led states to restrict medical treatments for transgender minors. During his second term, the president has pursued policies to end youth access to transition-related care through restrictive measures and federal investigations, following the implementation of a federal policy recognizing only male or female sexes assigned at birth. LGBTQ+ advocacy groups have consistently challenged these policies in court, condemning them as discriminatory and harmful.
Under the leadership of its president Andrew Ferguson, the Federal Trade Commission has investigated multiple medical organizations, including the American Academy of Pediatrics, regarding their public statements on youth gender-affirming care. Although the agency is not primarily a medical regulator, it has previously taken legal action against companies for allegedly deceptive marketing in the health product sector.
Defense Arguments and Prior Judicial Hurdles
The organization under scrutiny has previously defended its guidelines, maintaining that it supports personalized patient care rather than a uniform approach and that its standards rely on established science, expert consensus, and patient-centered values. In May, a federal judge blocked a prior agency subpoena directed at the group, ruling that the organization was likely to prove the investigation served as retaliation for its advocacy supporting gender-affirming care.
Medical treatments for gender transition encompass a spectrum of interventions, ranging from social adjustments such as pronouns and chosen names to puberty blockers, hormone therapy, and surgical procedures. As federal and state policies shift, some healthcare providers have stopped offering these services to minors, leaving affected families to consider relocating to alternative states to maintain access to care.
